We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
Read MoreHide Full Article
Haemonetics Corporation (HAE - Free Report) delivered adjusted earnings per share (EPS) of 77 cents in the fourth quarter of fiscal 2023, reflecting growth of 18.5% year over year. The bottom line surpassed the Zacks Consensus Estimate by 13.2%.
On a GAAP basis, the EPS was 57 cents compared with 19 cents in the prior-year quarter.
For the full year, adjusted earnings were $3.03 per share, 17.4% up from the year-ago period. The metric also beat the Zacks Consensus Estimate by 3.1%.
Total Revenues
Revenues increased 14.9% (up 17.2% on an organic basis) to $304.4 million in the fourth quarter of fiscal 2023. The top line beat the Zacks Consensus Estimate by 7%.
Haemonetics Corporation Price, Consensus and EPS Surprise
Full-year revenues were $1.17 billion, reflecting a 17.7% increase from the year-ago period (up 21% at the constant exchange rate or CER). Revenues surpassed the Zacks Consensus Estimate by 1.7%.
The unprecedented collections recovery in plasma volumes, the performance of hemostasis management and vascular closure and operational excellence toward greater productivity fueled Haemonetics’ strong performance throughout fiscal 2023.
Segments in Detail
At Plasma, revenues of $131.2 million (accounting for 43.1% of the total revenues) rose 29.8% year over year (up 31.2% on an organic basis) in the reported quarter.
Revenues at Blood Center (22.1%) fell 8.1% (down 3.7% on an organic basis) to $67.2 million.
Hospital revenues (33.1%) rose 17.6% (up 19.3% on an organic basis) to $100.8 million. primarily driven by growth in Vascular Closure and Hemostasis Management.
Service revenues (1.7%) increased 2.9% (up 6.8% on an organic basis) to $5.2 million.
Margins
In the fourth quarter of fiscal 2023, the company-adjusted gross margin was 51.8%, down 180 basis points (bps) year over year. The primary drivers of the decrease were inflationary pressures on global manufacturing and the supply chain, increased depreciation expenses and foreign exchange partially offset by volume and price benefits.
Company-adjusted operating expenses in the fourth quarter of fiscal 2023 were $103.6 million, up 8.7% from the year-ago quarter. The increase was primarily driven by performance-based compensations, investments in sales and marketing and R&D, partially offset by a decrease in freight costs and Operational Excellence Program savings.
The company-adjusted operating income was $53.9 million in the quarter under discussion, up 15.8% year over year. The adjusted operating margin was 17.7%, up 10 bps from the year-ago quarter.
Financial Position
Haemonetics exited fiscal 2023 with cash and cash equivalents of $284.5 million compared with $259.5 million at the end of the fourth quarter of fiscal 2022. The long-term debt at the end of the fiscal fourth quarter was $754.1 million, up from $559.4 million at the end of the fourth quarter of 2022.
The cumulative net cash flow from operating activities at the end of the fourth quarter of fiscal 2023 was $273.1 million compared to the $172.3 million cash inflow from operating activities a year ago.
As part of its previously announced $300 million share repurchase program, the company repurchased 997,406 shares of its common shares for $75.0 million via an accelerated share repurchase program in the fiscal second quarter. However, it did not repurchase any additional stock in the fourth quarter of 2023.
2024 Guidance
Haemonetics provided its outlook for fiscal 2024.
For 2024, the company expects total GAAP revenue growth in the range of 4%-7% on a reported basis. Organic revenue growth is anticipated at 5%-8%. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $1.19 billion.
HAE expects the full-year adjusted EPS in the band of $3.45-$3.75. The Zacks Consensus Estimate for the same is pegged at $3.29.
Our Take
Haemonetics ended the fourth quarter of fiscal 2023 with better-than-expected earnings and revenues. The robust volume growth and price benefits in the Plasma business drove the quarter’s top line.
Revenues from HAE’s hospital business came in at $100 million for the first time, which is highly appreciated. The Vascular Closure business favorably contributing toward operating margins also seems promising.
For fiscal 2023, Haemonetics generated $26 million in gross savings from its operational excellence program, with cumulative gross savings slightly ahead of the plan. The company continues to prioritize investments in high-impact and high-value projects, with plans to amplify the domestic production of NexSys PCS devices to support plasma customer growth requirements.
However, the year-over-year decline to flat revenue guidance in HAE’s Blood Center business is discouraging. The pacing of revenues in this business is backend loaded with an unfavorable order timing impact in the first half of the year compared with fiscal 2023.
Zacks Rank & Key Picks
Haemonetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Edwards Lifesciences Corporation (EW - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and Johnson & Johnson (JNJ - Free Report) .
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), reported a first-quarter 2023 adjusted EPS of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in the other, the average being 1.2%.
Intuitive Surgical, having a Zacks Rank #2, reported a first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate by 3.4%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%.
Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 1.9%.
Johnson & Johnson reported first-quarter 2023 adjusted earnings of $2.68 per share, beating the Zacks Consensus Estimate by 6.8%. Revenues of $24.75 billion surpassed the Zacks Consensus Estimate by 5%. It currently carries a Zacks Rank #2.
Johnson & Johnson has a long-term estimated growth rate of 5.5%. JNJ’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
Haemonetics Corporation (HAE - Free Report) delivered adjusted earnings per share (EPS) of 77 cents in the fourth quarter of fiscal 2023, reflecting growth of 18.5% year over year. The bottom line surpassed the Zacks Consensus Estimate by 13.2%.
On a GAAP basis, the EPS was 57 cents compared with 19 cents in the prior-year quarter.
For the full year, adjusted earnings were $3.03 per share, 17.4% up from the year-ago period. The metric also beat the Zacks Consensus Estimate by 3.1%.
Total Revenues
Revenues increased 14.9% (up 17.2% on an organic basis) to $304.4 million in the fourth quarter of fiscal 2023. The top line beat the Zacks Consensus Estimate by 7%.
Haemonetics Corporation Price, Consensus and EPS Surprise
Haemonetics Corporation price-consensus-eps-surprise-chart | Haemonetics Corporation Quote
Full-year revenues were $1.17 billion, reflecting a 17.7% increase from the year-ago period (up 21% at the constant exchange rate or CER). Revenues surpassed the Zacks Consensus Estimate by 1.7%.
The unprecedented collections recovery in plasma volumes, the performance of hemostasis management and vascular closure and operational excellence toward greater productivity fueled Haemonetics’ strong performance throughout fiscal 2023.
Segments in Detail
At Plasma, revenues of $131.2 million (accounting for 43.1% of the total revenues) rose 29.8% year over year (up 31.2% on an organic basis) in the reported quarter.
Revenues at Blood Center (22.1%) fell 8.1% (down 3.7% on an organic basis) to $67.2 million.
Hospital revenues (33.1%) rose 17.6% (up 19.3% on an organic basis) to $100.8 million. primarily driven by growth in Vascular Closure and Hemostasis Management.
Service revenues (1.7%) increased 2.9% (up 6.8% on an organic basis) to $5.2 million.
Margins
In the fourth quarter of fiscal 2023, the company-adjusted gross margin was 51.8%, down 180 basis points (bps) year over year. The primary drivers of the decrease were inflationary pressures on global manufacturing and the supply chain, increased depreciation expenses and foreign exchange partially offset by volume and price benefits.
Company-adjusted operating expenses in the fourth quarter of fiscal 2023 were $103.6 million, up 8.7% from the year-ago quarter. The increase was primarily driven by performance-based compensations, investments in sales and marketing and R&D, partially offset by a decrease in freight costs and Operational Excellence Program savings.
The company-adjusted operating income was $53.9 million in the quarter under discussion, up 15.8% year over year. The adjusted operating margin was 17.7%, up 10 bps from the year-ago quarter.
Financial Position
Haemonetics exited fiscal 2023 with cash and cash equivalents of $284.5 million compared with $259.5 million at the end of the fourth quarter of fiscal 2022. The long-term debt at the end of the fiscal fourth quarter was $754.1 million, up from $559.4 million at the end of the fourth quarter of 2022.
The cumulative net cash flow from operating activities at the end of the fourth quarter of fiscal 2023 was $273.1 million compared to the $172.3 million cash inflow from operating activities a year ago.
As part of its previously announced $300 million share repurchase program, the company repurchased 997,406 shares of its common shares for $75.0 million via an accelerated share repurchase program in the fiscal second quarter. However, it did not repurchase any additional stock in the fourth quarter of 2023.
2024 Guidance
Haemonetics provided its outlook for fiscal 2024.
For 2024, the company expects total GAAP revenue growth in the range of 4%-7% on a reported basis. Organic revenue growth is anticipated at 5%-8%. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $1.19 billion.
HAE expects the full-year adjusted EPS in the band of $3.45-$3.75. The Zacks Consensus Estimate for the same is pegged at $3.29.
Our Take
Haemonetics ended the fourth quarter of fiscal 2023 with better-than-expected earnings and revenues. The robust volume growth and price benefits in the Plasma business drove the quarter’s top line.
Revenues from HAE’s hospital business came in at $100 million for the first time, which is highly appreciated. The Vascular Closure business favorably contributing toward operating margins also seems promising.
For fiscal 2023, Haemonetics generated $26 million in gross savings from its operational excellence program, with cumulative gross savings slightly ahead of the plan. The company continues to prioritize investments in high-impact and high-value projects, with plans to amplify the domestic production of NexSys PCS devices to support plasma customer growth requirements.
However, the year-over-year decline to flat revenue guidance in HAE’s Blood Center business is discouraging. The pacing of revenues in this business is backend loaded with an unfavorable order timing impact in the first half of the year compared with fiscal 2023.
Zacks Rank & Key Picks
Haemonetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Edwards Lifesciences Corporation (EW - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and Johnson & Johnson (JNJ - Free Report) .
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), reported a first-quarter 2023 adjusted EPS of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in the other, the average being 1.2%.
Intuitive Surgical, having a Zacks Rank #2, reported a first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate by 3.4%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%.
Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 1.9%.
Johnson & Johnson reported first-quarter 2023 adjusted earnings of $2.68 per share, beating the Zacks Consensus Estimate by 6.8%. Revenues of $24.75 billion surpassed the Zacks Consensus Estimate by 5%. It currently carries a Zacks Rank #2.
Johnson & Johnson has a long-term estimated growth rate of 5.5%. JNJ’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.9%.